Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    Agriculture & Environment
    Addressing Climate Change
    Strengthening the Bioeconomy
    Growing Trust in Innovation
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member ag&evnt
    Agriculture & Environment
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    Agriculture & Environment
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 16-19, 2025 | Boston, MA

    Learn More
    BIO Asia-Taiwan
    BioSafe General Membership Meeting

    April 7-9, 2025
    Basel, Switzerland

    BIO Investor Forum
    Partnering @JPM Week

    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO CEO & Investor Conference

    Miami, FL | 2026

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyAgriculture & EnvironmentInternationalIntellectual PropertyAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthAgriculture & EnvironmentStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3088 results found
Expand All
Apply All
3088 results found

BIO Submits Comments Re: Medicare CY 2018 Updates to the Quality Payment Program
Share
Letters, Testimony & Comments  •  August 23, 2017
BIO submitted comments in response to the Centers for Medicare and Medicaid Services' (CMS's) CY 2018 Updates to the Quality Payment Program Proposed Rule. BIO supports the development and implementation of the Quality Payment Program (QPP) tracks: Advanced Alternative Payment Models (APMs) and the Merit Based Incentive Payment System (MIPS), in a manner that improves overall healthcare quality, while not compromising access to the most appropriate care and treatment.
Read More

BIO Applauds Signing of Food and Drug Administration Reauthorization Act (FDARA)
Share
Press Release  •  August 18, 2017
Enactment of FDA User Fee package important victory for patients, medical innovation
Read More

Fireside Chat Speakers, Programming Announced for 2017 BIO Investor Forum
Share
Press Release  •  August 15, 2017
BIO announces programming for the upcoming BIO Investor Conference Oct. 17-18 in San Francisco including Kristina Burow, Managing Director of ARCH Venture Partners and Dr. Richard Scheller, Chief Science Officer & Head of Therapeutics for 23andMe. The annual conference explores global investment trends and opportunities in life sciences. Early and mid-stage private as well as emerging public companies poised for growth in 2018 are the focus of the event.  
Read More

BIO files Amicus Brief in Patent Case Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc. (U.S. Court of Appeals for the Federal Circuit)
Share
Amicus Brief  •  August 14, 2017
BIO submitted an amicus brief in the U.S. Court of Appeals for the Federal Circuit, supporting Acorda Therapeutics and reversal. 
Read More

BIO Submits Comments Re: Hospital Inpatient Prospective Payment Systems (IPPS) Proposed Rule
Share
Letters, Testimony & Comments  •  August 8, 2017
BIO submitted comments in response to the Centers for Medicare and Medicaid Services' (CMS's) Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System Proposed Policy Changes and Fiscal  Year 2018 Rates Proposed Rule on June 13, 2017. BIO supports the development and use of appropriate, evidence-based quality measures throughout the healthcare system as a component of improving efficiency and clinical outcomes; additionally, we support policy proposals driven at increasing access to innovative care. BIO's comments in the letter are divided into two sections - the first focusing on the proposals contained in the FY 2018 Proposed Rule, and the second for providing feedback on the Request for Information.
Read More

BIO: Senate Passage of FDA User Fee Package Important Victory for Patients, Medical Innovation
Share
Press Release  •  August 3, 2017
Washington, DC (August 3, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S. Senate today:
Read More

BIO's 2017 Special 301 Submission
Share
Letters, Testimony & Comments  •  July 31, 2017
BIO submitted a report to the United States Trade Representative regarding the agency’s 2017 Special 301 Review.
Read More

BIO Applauds US Court of Appeals Decision on the Renewable Fuel Standard
Share
Press Release  •  July 28, 2017
The U.S. Court of Appeals for the District of Columbia Circuit today supported BIO's argument that the RFS statute does not allow EPA to rely on demand-side factors under the oil industry’s control as a basis for setting annual renewable fuel volumes.
Read More

BIO Submits Comments on Program for Enhanced Review Transparency and Communication for Original 351(k) Biologics License Applications in Biosimilar User Fee Act II
Share
Letters, Testimony & Comments  •  July 27, 2017
BIO submitted comments to the Food and Drug Administration (FDA) on the statement of work for assessment of the Program for Enhanced Review Transparency and Communication for Original 351(k) Biologics License Applications in Biosimilar User Fee Act II. BIO supports the approach described in the BsUFA II Performance Goals of establishing a review approach for biosimilars applications patterned generally after the program established under PDUFA V for New Molecular Entity (NME) and new Biological License Applications (BLAs). BIO agrees the evaluation must be public, include input from FDA staff and sponsors, and provide recommendations at the mid-point and at the end of the program for any changes necessary for the program to succeed.
Read More

The 2017 BIO World Congress Comes to a Close in Montreal
Share
Agriculture & Environment, BIO One-on-One Partnering  •  Press Release  •  July 26, 2017
The 14th annual BIO World Congress drew 954 attendees. The world’s largest industrial biotechnology event hosted more than 227 speakers in seven education tracks and five plenaries and set a new conference record for partnering meetings.
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 276
  • 277
  • 278
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO International Convention
BIO Partnering at JPM Week
BIO CEO & Investor Conference
BIO Investor Forum
BIO Patient Health & Advocacy Summit
BIO Intellectual Property Counsels Committee Conference
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO